Allergy Therapeutics plc (LON:AGY – Get Free Report) reached a new 52-week high during trading on Monday . The company traded as high as GBX 7.50 ($0.09) and last traded at GBX 7.20 ($0.09), with a volume of 2510080 shares trading hands. The stock had previously closed at GBX 7 ($0.09).
Allergy Therapeutics Stock Performance
The stock has a market cap of £348.21 million, a P/E ratio of -121.67, a PEG ratio of -30.70 and a beta of 1.40. The company has a debt-to-equity ratio of 37.22, a current ratio of 1.40 and a quick ratio of 1.48. The company has a fifty day moving average of GBX 5.83 and a 200 day moving average of GBX 5.15.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Featured Articles
- Five stocks we like better than Allergy Therapeutics
- 3 Warren Buffett Stocks to Buy Now
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- Financial Services Stocks Investing
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
